Advances in Anaplastic Thyroid Cancer Research and Treatment
The landmark clinical trial of dabrafenib and trametinib led to FDA approval for BRAFV600E‑mutated anaplastic thyroid cancer in 2018.
A comprehensive overview of recent advances in the research and treatment of anaplastic thyroid cancer (ATC) at MD Anderson Cancer Center, highlighting clinical trials, drug approvals, genetic discoveries, and ongoing multidisciplinary research programs.
This landmark approval marked the first targeted therapy option for a historically refractory malignancy and dramatically improved median overall survival for patients with BRAF‑mutated ATC.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management